We are pulmonary hypertension professionals united in our vision for a world without pulmonary vascular disease. We believe we can achieve this together, and we won’t stop until we do.
PVRI 2026 registration & abstract portal open
Taking place 28 January – 1 February in Dublin, with the theme Celebrating 20 Years of Progress & Innovation to mark our 20th anniversary year, we invite you to join global leaders in PH for cutting-edge research, lively discussion, and impactful networking.
Our PHGPS has released initial findings from its adult cohort in a paper published in the ERJ Open Research. Initial findings have also identified 10 global calls to action for improving PH care, which aim to enhance equitable access to care and research opportunities, particularly across areas of geographical disparities.
Whether you’re a pulmonary hypertension specialist, a pharmaceutical or industry colleague, a regulator, a patient, or a caregiver, joining our growing global family means you share our vision to reduce the global burden of pulmonary vascular disease.
Join an esteemed panel of international leaders as they share their approaches to bridging pediatric patients to lung transplantation. This dynamic session will feature focused presentations from each speaker, followed by interactive panel discussions of two real-world clinical cases.
'Pulmonary hypertension in the shadow of infections: challenges in Indian practice' is part of the Virtual Symposium series by the iPVD, a global education programme that highlights top-notch research on inflammation and infectious PVD.
To kick off the relaunch of the Women’s Health Task Force, co-chairs Jessica Badlam, University of Vermont Medical Center, and Meghan Cirulis, Intermountain Health Intermountain Medical Center, have put together a dedicated webinar exploring the intersection of women’s health and pulmonary vascular disease. The session will feature expert scientific presentations and open discussion, with time set aside to introduce the Task Force’s renewed objectives and future goals.
Part of the 'Hypoxia in pulmonary vascular research – altitude and beyond' webinar series by the High Altitude Task Force, who raise awareness and understanding of PH linked to high altitude and organise scientific conferences in regions affected by high altitudes.
In a recent study conducted by Laura Stourm et al., the authors identified that patients with pulmonary hypertension (PH) harboring loss-of-function variants in the Filamin A (FLNA) gene exhibit a unique spectrum of phenotypes. These include pulmonary involvement with lung parenchymal abnormalities and emphysema, as well as a range of extrapulmonary manifestations such as dysmorphic facial features, epilepsy, congenital heart defects, valvular and aortic diseases, thrombocytopenia, and periventricular nodular heterotopia (PVNH).
Portopulmonary hypertension (PoPH), a type of pulmonary arterial hypertension (PAH) in patients with liver disease, is associated with high morbidity and mortality. The relationship between cardiopulmonary hemodynamics, PAH therapy, and survival in PoPH remains unclear.
We’re thrilled to announce a new chapter in the leadership of PVRI’s Innovative Drug Discovery Initiative (IDDI). We warmly welcome industry reps, Gil Golden (UTC) and Sidra Hoffman (Gossamer Bio), to the IDDI Leadership Team. They’ll be joining Sandeep Sahay and Luke Howard, who remain on as IDDI Leaders.
Your feedback is needed on our work groups and subject areas...We’re reviewing some of our IDDI Workstream activity, and we need you to help us shape the future agenda.
We’re pleased to share that the Pulmonary Hypertension Global Patient Survey (PHGPS) - a key project of the IDDI Patient Engagement & Empowerment (PE&E) Workstream - is now a stand-alone Task Force.
